Role of associating liver partition and portal vein ligation for staged hepatectomy in colorectal liver metastases: A review

Table 1 Diagnoses and number of patients with each diagnosis

Diagnosis	Number
CRLM	68
Liver metastasis	39
CCA including Klatskin	32
HCC	8
Gallbladder cancer	2
Sarcoma	2
Malignant epithelioid hemangioendothelioma	1
Cystic liver disease	1
Metastatic ovarian cancer	1
Metastatic gastric cancer	1
GIST	1
Barrett-Ca	1

CRLM: Colorectal liver metastases; CCA: Cholangiocarcinoma; HCC: Hepatocellular carcinoma; GIST: Gastrointestinal stromal tumor.

Table 2 Age, sex and American Society of Anesthesiologist physical status classification system of patients in the included papers, number of patients with colorectal liver metastases and chemotherapy

Ref.	Age (median and range)	Sex	ASA	Number of patients with CRLM	Neoadjuvant chemotherapy
Schnitzbauer et al[20]	63 (32-75)	14 M, 11 F		14	11 CRLM (7 folfox, 1 folfox + cetuximab, 1 folfox + bevacizumab, 1 xeliri + cetuximab, 1 xelox), 1 gastric cancer (flot3)
Torres et al[37]	57.3 (20-83)	22 M, 17 F		7	Not specified
Oldhafer et al[25]	65 (52-81)	4 M, 3 F			2 (folfox + bevacizumab, folfiri + bevacizumab/HD-5FU)
Ratti et al[24]	61 (45-72)	6 M, 2 F	7 ASA 2, 1 ASA 3	5	5 CRLM (folfiri + bevacizumab, folfox + bevacizumab, folfiri + cetuximab, folfiri, folfox + cetuximab)
Nadalin et al[21]	67 (43-80)	7 M, 8 F	10 ASA 2, 3 ASA 5	5	5 CRLM (4 folfox, 1 folfiri)
Ielpo et al[38]	58.5 (56-63)	2 M, 4 F		5	5 CRLM, regimen not specified
Schadde et al[39]	57 (48.5-65)	29 M, 19 F	40 ASA 1-2, 8 > 2	26	28, diagnosis and regimen not specified
Gauzolino et al[40]	52.5 (49-67)	3 M, 1 F		4	2 oxaliplation, 2 irinotecan
Troja et al[41]	65 (38-72)	4 M, 1 F		2	1 CRLM (folfiri + bevacizumab), 1 (imatinib/sunitinib, 1 cisplatin/5-FU)

CRLM: Colorectal liver metastases; CCA: Cholangiocarcinoma; HCC: Hepatocellular carcinoma; GIST: Gastrointestinal stromal tumor; ASA: American Society of Anesthesiologist physical status classification system; M: Male; F: Female.

Table 3 Pre- and postoperative volume of future liver remnant, increase of future liver remnant and time for increase

Ref.	Preoperative volume of FLR1	Postoperative volume of FLR1	Increase	Time
Schnitzbauer et al[20]	FLR/BWR 0.38 (0.25-0.49)	FLR/BWR 0.61	74% (21-192)	9 (5-28)
Torres et al[37]	-	-	83% (47-211.9)	14.1 (5-30)
Oldhafer et al[25]	23.8% (13.1-37.2)	36.7% (22.4-59.5)	65% (16-97)	13 (10-40)
Ratti et al[24]	22% (16-27)	33% (31-40)	-	7.5
Nadalin et al[21]	22.6% (15.7-29.2)	36.3% (30-59.2)	87.2% (23.8-161)	10 (8-16)
Ielpo et al[38]	-	-	95.5% (56-214)	15 (12-21)
Schadde et al[39]	23% (18-29%)	41% (34-47%)	77.4% (52.8-101.7)	-
Gauzolino et al[40]	31% (20-47)	43.5% (32-52)	-	-
Troja et al[41]	-	-	-	14 (14-21)

¹The future liver remnant (FLR) is expressed as a percentage of the TLV.

Table 4 Number of patients in each report and distribution of postoperative complications

Ref.	Number of patients	Grade I	II	III	IV	V
Schnitzbauer et al[20]	25	12	13	6 IIIa, 8 IIIb	3 Iva, 5 IVb	31
Torres et al[37]	39	2	-	-	-	5
Oldhafer et al[25]	7	11	41	11
Ratti et al[24] after step 1	8		1		2
After step 2				3 IIIa		1
Nadalin et al[21] after step 1	15	12 (I/II)		3 IIIa, 2 IIIb	2
After step 2	15	16 I/II		5 IIIa, 4 IIIb	7	4
Ielpo et al[38]	6	3			2 IVa	11
Schadde et al[39]	48	3
Gauzolino et al[40]	4	2		1 IIIb
Troja et al[41]	5		3	1		1

¹Patients with CRLM;

²18 patients had significant morbidity;

³After step 1: 21 complications, 7 with grade IIIb or higher; after step 2: 35 complications, 13 with grade IIIb or higher.